Cameron Health, Inc. announced the commencement of the CE trial implants in Europe and New Zealand with the Subcutaneous Implantable Defibrillator (S-ICD) System. This S-ICD System is intended for use in patients at risk of Sudden Cardiac Arrest (SCA). The minimally invasive S-ICD system implantation is entirely subcutaneous; no leads are in or on the heart. No imaging equipment is required for placement of the S-ICD System, as all of the components may be positioned using anatomical landmarks. The company’s S-ICD System resides just under the skin, potentially avoiding many of the complications associated with the conventional implant procedure and long term performance. This implantable system is designed for ease of placement and removal while shortening the surgical procedure time. As a part of the CE trial, 14 patients have received an S-ICD System, which will involve up to 55 patients at 10 centers in Europe and New Zealand. Implants performed in New Zealand were conducted by Dr. Margaret Hood at Auckland City Hospital and by Dr. Ian Crozier at Christchurch Hospital. Initial implants in Europe were under the direction of Dr. Riccardo Cappato at Policlinico San Donato Milanese Hospital in Italy and Professor Luc Jordaens at Erasmus Medical Center in the Netherlands